(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

Watchdog finds failings in prostate cancer treatment in North Wales going back almost a decade.

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

Early-stage prostate cancer rarely causes symptoms, making routine screening the most reliable way to catch it before it ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer.

This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." ...

The effects of the extent of lymph node dissection during radical prostatectomy on prostate cancer survival outcomes have been unclear, pending long-term follow-up data from randomized controlled ...

Read more about the factors that patients with prostate cancer value most in treatment decisions, as reported at EAU 2026.

Radiation therapy (also called radiotherapy) uses high-energy beams or subatomic particles to damage the DNA inside prostate cancer cells. After enough damage, the cells cannot multiply, and they die.

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.